13209-41-1
13209-41-1 結(jié)構(gòu)式
基本信息
地塞米松EP雜質(zhì)E
糠酸莫米松雜質(zhì)22
地塞米松磷酸鈉雜質(zhì)E
地塞米松雜質(zhì)E(EP)
地塞米松磷酸鈉雜質(zhì)EP F
地塞米松磷酸鈉雜質(zhì)EP E
16Α-甲基-9,11-脫氫潑尼松龍
Dexamethasone impurity E
Dexamethasone Impurity L
(8S,10S,13S,14S,16R,17R)-17-hydroxy
16α-Methyl-9,11-dehydro Prednisolone
Dexamethasone Impurity 5(Dexamethasone EP Impurity E)
17,21-dihydroxy-16alpha-methylpregna-1,4,9(11)-triene-3,20-dione
17, 21-dihydroxy-16α-methylpregna- 1, 4, 9(11)-triene-3,20-dione
(16α)-17,21-Dihydroxy-16-Methylpregna-1,4,9(11)-triene-3,20-dione
17.alpha.,21-Dihydroxy-16.alpha.-methylpregna-1,4,9(11)-triene-3,20-dione
物理化學(xué)性質(zhì)
常見問題列表
Vamorolone (VBP15) inhibits TNFα-induced pro-inflammatory NF-κB signaling in C2C12 muscle cells at 1 nM or more. Vamorolone binds the glucocorticoid receptor (GR) and mineralocorticoid receptor (MR) with similar affinity.
Vamorolone (0.1, 1μM; 30 minutes) reduces production of IL1βand CCL5 inflammatory mediators in primary human macrophages.
Vamorolone is a first-in-class mineralocorticoid receptor (MR) antagonist/dissociative glucocorticoid receptor (GR) ligand.
Vamorolone (5-30 mg/kg; cherry syrup) shows a superior side effect profile compared to pharmacological glucocorticoids in
mdx
mice.
Vamorolone (30 mg/kg; orally; daily for 20 days) reduces CNS Inflammation in murine experimental autoimmune encephalomyelitis.
| Animal Model: | C57BL/6 mice (experimental autoimmune encephalomyelitis) |
| Dosage: | 30 mg/kg |
| Administration: | Orally; daily for 20 days (starting one day prior to MOG 33-55 peptide immunization and continuing) |
| Result: | Reduced CNS inflammation in murine experimental autoimmune encephalomyelitis. |